论文部分内容阅读
目的探讨鲑降钙素注射液治疗骨质疏松的临床疗效。方法选取2013年5月—2014年5月玉林市中西医结合骨科医院收治的骨质疏松患者79例,根据患者入院尾号分为对照组39例与治疗组40例。对照组患者予以维生素D2磷葡钙片治疗,治疗组患者在对照组基础上予以鲑降钙素注射液治疗。观察两组患者治疗前后骨密度(BMD)、治疗前、治疗1、2、3个月视觉模拟评分法(VAS)评分、血生化指标(血骨钙素、血磷、血钙、碱性磷酸酶、尿钙/尿肌酐、羟脯氨酸/尿肌酐)、临床疗效及不良反应发生情况。结果治疗前两组患者L2~4、左侧股骨颈BMD比较,差异无统计学意义(P>0.05),治疗后治疗组患者L2~4、左侧股骨颈BMD高于对照组,差异有统计学意义(P<0.05);VAS评分时间与方法间有交互作用(P<0.05),时间间比较,差异有统计学意义(P<0.05),组间比较,差异有统计学意义(P<0.05),治疗前两组患者VAS评分比较,差异无统计学意义(P>0.05),治疗1、2、3个月治疗组患者VAS评分低于对照组,差异有统计学意义(P<0.05);治疗前两组患者血骨钙素、血磷、血钙、碱性磷酸酶、尿钙/尿肌酐、羟脯氨酸/尿肌酐比较,差异无统计学意义(P>0.05),治疗后治疗组患者血骨钙素、血磷、碱性磷酸酶、羟脯氨酸/尿肌酐高于对照组,差异有统计学意义(P<0.05),治疗后两组患者血钙、尿钙/尿肌酐比较,差异无统计学意义(P>0.05);治疗组患者总有效率高于对照组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论鲑降钙素注射液治疗骨质疏松的临床疗效显著,可减轻患者疼痛,提高患者生活能力,且不良反应少。
Objective To investigate the clinical efficacy of salmon calcitonin injection in the treatment of osteoporosis. Methods From May 2013 to May 2014, 79 cases of osteoporosis patients admitted to Integrative Medicine Hospital of Yulin City were divided into control group (39 cases) and treatment group (40 cases). Patients in the control group were treated with vitamin D2 phosphate and calcium phosphate tablets. Patients in the treatment group were treated with salmon calcitonin injection on the basis of the control group. The bone mineral density (BMD) before and after treatment was observed before treatment. The visual analog scale (VAS) score, blood biochemical indexes (serum osteocalcin, serum phosphorus, serum calcium and alkaline phosphatase Enzyme, urinary calcium / urine creatinine, hydroxyproline / urinary creatinine), clinical efficacy and adverse reactions. Results There was no significant difference in L2 ~ 4 and left femoral neck BMD between the two groups before treatment (P> 0.05). After treatment, the BMD of L2 ~ 4 and left femoral neck in the treatment group was higher than that in the control group (P <0.05). There was interaction between time and method of VAS score (P <0.05), and the difference was statistically significant (P <0.05), the difference was statistically significant (P < 0.05). There was no significant difference in VAS score between the two groups before treatment (P> 0.05). The VAS score of the treatment group was lower than that of the control group ); There was no significant difference in the levels of serum osteocalcin, serum phosphorus, serum calcium, alkaline phosphatase, urinary calcium / urinary creatinine, hydroxyproline / urinary creatinine between the two groups before treatment (P> 0.05) After treatment, the levels of serum osteocalcin, serum phosphorus, alkaline phosphatase, hydroxyproline and urinary creatinine in the treatment group were significantly higher than those in the control group (P <0.05). After treatment, serum calcium and urinary calcium / Urine creatinine, the difference was not statistically significant (P> 0.05); The total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P <0.05); The incidence of adverse reactions in both groups was significantly different Statistically significant (P> 0.05). Conclusion Salmon calcitonin injection treatment of osteoporosis significant clinical efficacy, can reduce pain and improve patient life, and fewer adverse reactions.